SCHEMBL24254564

SCHEMBL24254564

CN(C)S(=O)(=O)c1ccc(OC(F)(F)F)c(NC(=O)Cc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
RORC P51449 7/20 0.47
GSTO1 P78417 1/20 0.47
CTSD P07339 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 1/20 0.46
KCNJ6 P48051 1/20 0.46
KCNJ5 P48544 1/20 0.46
KCNJ3 P48549 1/20 0.46
CSNK1D P48730 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254485 0.85 ALDH1A1 (0.60) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL24254502 0.82 ALDH1A1 (0.66) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL24254497 0.81 ALDH1A1 (0.56) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL24254517 0.79 GSTO1 (0.49) ALDH1A1LMNAMAPTSMN1; SMN2GSTO1
SCHEMBL24254529 0.77 ALDH1A1 (0.53) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL24254505 0.75 LMNA (0.79) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL26188053 0.71 VCAM1 (0.57) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL26188145 0.71 ALDH1A1 (0.64) ALDH1A1LMNAMAPT
SCHEMBL26188045 0.70 ALDH1A1 (0.57) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL26188049 0.69 ALDH1A1 (0.64) ALDH1A1LMNAMAPTSMN1; SMN2KCNJ6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885LMNA 3727/4885MAPT 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.